A new strategy to improve transplant survival in diabetic patients is presented online in Nature Medicine.
In some individuals, Type 1 diabetes can be treated by transplanting pancreatic islets, but long-term survival of the transplants has been difficult to achieve. Islet grafts are rejected by the immune system, and efforts to increase their survival are usually aimed at dampening immune T-cell function.
Because B cells -- another type of immune cell -- may also play a role in graft rejection, Ali Naji and colleagues tested the effect of depleting B cells in monkeys transplanted with islet allografts. The authors found that rituximab, a B-cell depleting antibody approved for the treatment of Non-Hodgkin's Lymphoma and rheumatoid arthritis, in combination with T-cell depleting therapy could extend survival of the grafts in some animals.
Long-term graft survival also normalized blood sugar levels, suggesting that B-cell depletion should be studied further for its potential benefit to therapies aimed at improving survival of islet transplants used to treat Type 1 diabetes.
Ali Naji (University of Pennsylvania School of Medicine, Philadelphia, PA, USA)
Abstract available online.
(C) Nature Medicine press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking